Page last updated: 2024-12-07

1,3-didecanoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

## 1,3-Didecanoylglycerol: A Key Player in Fat Metabolism Research

1,3-didecanoylglycerol (1,3-DDG) is a **monoacylglycerol** (MAG) with two decanoic acid (capric acid) molecules attached to the glycerol backbone. This specific arrangement of fatty acids makes it a crucial molecule for studying **fat metabolism** and its associated health implications.

Here's why 1,3-DDG is important in research:

**1. Precursor to Monoglycerides:** 1,3-DDG is a **major intermediate** in the **digestion and absorption of dietary fats**. It forms through the action of lipases, enzymes that break down triglycerides into fatty acids and glycerol. This process occurs in the small intestine and is crucial for delivering fatty acids to various cells.

**2. Signaling Molecule:** 1,3-DDG has **signaling roles** within the body, particularly in:

* **Energy metabolism:** 1,3-DDG can act as a **ligand** for specific receptors (like GPR119), triggering various metabolic responses including **glucose homeostasis** and **insulin secretion**. This role makes it a potential target for treating metabolic disorders like **diabetes**.
* **Fatty acid synthesis:** 1,3-DDG also plays a role in **regulating de novo lipogenesis**, the process of creating new fatty acids from carbohydrates. This could potentially lead to insights into managing **obesity** and related conditions.

**3. Therapeutic Potential:** Research on 1,3-DDG is exploring its therapeutic potential in various areas like:

* **Metabolic disorders:** Its ability to influence glucose and insulin levels makes 1,3-DDG a promising candidate for developing new **anti-diabetic drugs**.
* **Cardiovascular disease:** 1,3-DDG might help **regulate blood lipid levels**, potentially offering benefits in treating cardiovascular diseases.
* **Inflammation:** Research suggests 1,3-DDG might possess **anti-inflammatory properties**, contributing to its potential role in treating inflammatory diseases.

**4. Model for Studying Fat Metabolism:** 1,3-DDG serves as a valuable tool for studying **fat absorption and metabolism**. Researchers can utilize it to:

* **Analyze the activity of lipases** and other enzymes involved in fat digestion.
* **Investigate the role of different fatty acids** in various metabolic processes.
* **Develop and test new drugs** that target specific aspects of fat metabolism.

**Overall, 1,3-didecanoylglycerol is a crucial molecule in fat metabolism research, offering insights into the intricate processes of digestion, absorption, and utilization of dietary fats. Its potential as a signaling molecule and therapeutic agent opens exciting avenues for treating various metabolic disorders.**

Cross-References

ID SourceID
PubMed CID104665
SCHEMBL ID896977
MeSH IDM0097260

Synonyms (28)

Synonym
decanoic acid, 2-hydroxy-1,3-propanediyl ester
(3-decanoyloxy-2-hydroxy-propyl) decanoate
didecanoic acid, diester with glycerol
17598-93-5
2-hydroxypropane-1,3-diyl didecanoate
(3-decanoyloxy-2-hydroxypropyl) decanoate
glycerol 1,3-dicaprinate
1,3-didecanoyl glycerol
1,3-dicaprin
1,3-didecanoylglycerol
einecs 258-903-2
53988-07-1
FT-0637571
glyceryl-1,3-dicaprate
39I32HI5LO
glyceryl 1,3-dicaprate
SCHEMBL896977
2-hydroxypropane-1,3-diyl bis(decanoate)
decanoin, 1,3-di-
1,3-bis(decanoyloxy)glycerol
dg(10:0/0:0/10:0)
1,3-didecanoin
didecanoin
DTXSID90938727
n-cyanoacetamidesodiumsalt
Q27256902
decanoic acid, diester with 1, 2 ,3-propanetriol
AKOS040749881
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]